Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Fuji
Accenture
Boehringer Ingelheim
Deloitte
Mallinckrodt
Covington
QuintilesIMS
Daiichi Sankyo

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,791,270

« Back to Dashboard

Which drugs does patent 8,791,270 protect, and when does it expire?

Patent 8,791,270 protects BENDEKA and TREANDA and is included in two NDAs.

Protection for TREANDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-two patent family members in twenty-one countries.
Summary for Patent: 8,791,270
Title:Bendamustine pharmaceutical compositions
Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
Inventor(s): Brittain; Jason Edward (El Cajon, CA), Franklin; Joe Craig (Tulsa, OK)
Assignee: Cephalon, Inc. (Frazer, PA)
Application Number:13/969,724
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,791,270
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 8,791,270

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eagle Pharms BENDEKA bendamustine hydrochloride SOLUTION;IV (INFUSION) 208194-001 Dec 7, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA ➤ Try a Free Trial
Cephalon TREANDA bendamustine hydrochloride POWDER;IV (INFUSION) 022249-002 May 1, 2009 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Cephalon TREANDA bendamustine hydrochloride POWDER;IV (INFUSION) 022249-001 Mar 20, 2008 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Cephalon TREANDA bendamustine hydrochloride SOLUTION;IV (INFUSION) 022249-003 Sep 13, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,791,270

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,609,863 Bendamustine pharmaceutical compositions ➤ Try a Free Trial
8,436,190 Bendamustine pharmaceutical compositions ➤ Try a Free Trial
8,895,756 Bendamustine pharmaceutical compositions ➤ Try a Free Trial
8,461,350 Bendamustine pharmaceutical compositions ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,791,270

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 052877 ➤ Try a Free Trial
Australia 2006204817 ➤ Try a Free Trial
Brazil PI0606332 ➤ Try a Free Trial
Canada 2593582 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Julphar
Teva
Citi
Baxter
Fuji
Cantor Fitzgerald
Daiichi Sankyo
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.